PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

PepGen has previously faced an FDA clinical hold on the investigational new drug application of PGN-ENO51 in the Phase II ...

While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

PepGen (NASDAQ:PEPG – Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, ...

PepGen (PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne ...

About PGN-EDO51 PGN-EDO51, PepGen's investigational candidate in development for the treatment of DMD, utilizes the Company's proprietary Enhanced Delivery Oligonucleotide (EDO) technology to ...

PepGen paused its Phase 2 CONNECT2 study of PGN-EDO51 in DMD to review 10 mg/kg cohort data from CONNECT1, expected in Q3 2025. No new safety concerns have emerged and the company aims to refine ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular ...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment ...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment ...

After PepGen (PEPG) announced initial clinical data from the five and ten mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial ...

PepGen shares are trading higher by 125% during Monday's session. The company announced early data from its FREEDOM-DM1 trial for myotonic dystrophy. Our government trade tracker caught Pelosi’s ...